These data suggest that this novel approach—putting more emphasis on activities in tumor-draining lymph nodes—will enable us to develop a predictive biomarker for anti-PD-L1 antibodies such as atezolizumab, and this concept may extend further and be applicable to other immune checkpoint inhibitors. The gene discussed is CD274; the disease is neoplasm.